

7.9.9. Longcarcinoom: Literatuur en referenties

1. Niet-invasieve stadiëring longcarcinoom

- American Thoracic Society (ATS), European Respiratory Society (ERS). Pretreatment evaluation of non-small cell lung cancer. *Am J Respir Crit Care Med* 1997; 156:320-332.
- Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - what limits limited disease? *Lung Cancer* 2002; 37:271-276.
- Mountain CF. Revisions in the international system for staging lung cancer. *Chest* 1997; 111:1710-1717.
- Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. *J Clin Oncol* 2004; 22:330-353.
- Postmus PE, Rocmans P, Asamura H, et al. IASLC consensus report: pretreatment minimal staging for non-small cell lung cancer. *Lung Cancer* 2003; 42 Suppl 1:3S-6S.
- Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F. The noninvasive staging of non-small cell lung cancer: The guidelines. *Chest* 2003; 123 Suppl 1:147S-156S.
- Spira A, Ettinger DS. Multidisciplinary management of lung cancer. *N Engl J Med* 2004; 350:379-392.
- Spiro SG, Porter JC. Lung cancer-where are we today? Current advances in staging and non-surgical treatment. *Am J Respir Crit Care Med* 2002; 166:1166-1196.
- Stahel RA, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus. *Lung Cancer* 1989; 5:119-126.
- Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: A review of the current evidence. *Chest* 2003; 123 Suppl 1:137S-146S.
- Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. *J Clin Oncol* 1998; 16:2142-2149.

2. Invasieve locoregionale stadiëring van longcarcinoom

- Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. *Chest* 1997; 111:1718-1723.
- Toloza EM, Harpole L, Detterbeck F, McCrory DC. Invasive staging of non-small cell lung cancer: a review of the current evidence. *Chest* 2003; 123 Suppl 1:157S-166S.

3. Preoperatieve functionele evaluatie

- ATS/ERS statement: Pretreatment evaluation of NSCLC. *Am J Respir Crit Care Med* '97. Vol 156, p 320-332.
- Medical evaluation of the patient with potentially respectable lung cancer. *Lung cancer: Principles and practice*, 1996. Chapter 31: p 511-534.
- Guidelines on the selection of patients with lung cancer for surgery. *Thorax* 2001; 56: 89-108.
- Guidelines for perioperative cardiovascular evaluation for noncardiac surgery: an abridged version of the report of the American College of Cardiology/American Heart Association task force on practical guidelines. Eagle et al, *Mayo Clin Proc* 1997; 72: 524-531.

4. Behandeling van vroege stadia Niet Kleincellig Longcarcinoma (NKCLC)

- Blum RH. Adjuvant chemotherapy for lung cancer - a new standard of care. *N Engl J Med* 2004; 350:404-405.
- Bradley JD, Wahab S, Lockett MA, Perez CA, Purdy JA. Elective nodal failures are uncommon in medically inoperable patients with stage I non-small cell lung carcinoma treated with limited radiotherapy fields. *Int J Radiat Oncol Biol Phys* 2003; 56:342-347.
- Gauden S, Ramsay J, Tripcony L. The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. *Chest* 1995; 108:1278-1282.
- Smythe WR. Treatment of stage I non-small cell lung carcinoma. *Chest* 2003; 123 Suppl 1:181S-187S.
- Spira A, Ettinger DS. Multidisciplinary management of lung cancer. *N Engl J Med* 2004; 350:379-392.
- The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. *N Engl J Med* 2004; 350:351-360.

5. Behandeling van potentieel resecabel stadium III NKCLC

- Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. *J Clin Oncol* 2000;18:2981-2989.
- Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. *Ann Thorac Surg* 2000; 70:1826-1831.
- De Leyn P, Schoonhooghe P, Deneffe G, et al. Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease). *Eur J Cardiothorac Surg* 1996; 10:649-655.
- Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I, II, and IIIA non-small-cell lung cancer. *J. Clin Oncol* 2001;20:247-253.
- Detterbeck FC. *Diagnosis and treatment of lung cancer. An evidence-based guide for the practicing clinician.* W.B. Saunders company 2001. ISBN 0-7216-9192-7.

- Fernando HC, Goldstraw P. The accuracy of clinical intrathoracic staging as assessed by postsurgical pathological stage. *Cancer* 1990; 65:2503-2506.
- Funatsu T, Matsubaru Y, Hatakenaka R, et al. The role of mediastinoscopic biopsy in preoperative assessment of lung cancer. *J Thorac Cardiovasc Surg* 2002; 104: 1688-1695.
- Lorent N, De Leyn P, Lievens Y, et al. Long-term survival of surgically staged IIIA-N2 non-small cell lung cancer treated with surgical combined modality approach: analysis of a 7-year experience. *Ann Oncol* 2004; 15:1645-1653.
- Martini N, Yellin A, Ginsberg RJ, et al. Management of non-small-cell lung cancer with direct mediastinal involvement. *Ann Thorac Surg* 1994;58:1447-1451.
- Pearson FG, Delarue NC, Ilves R, et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. *J Thorac Cardiovasc Surg* 1982; 83:1-11.
- PORT meta-analysis Trialists Group. Postoperative Radiotherapy in non-small-cell lung cancer. Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. *Lancet* 1998; 352:257-263.
- Robinson L, Wagner H, Ruckdeschel JC. Treatment of stage IIIA non-small cell lung cancer. *Chest* 2003; 123:202S-220S.
- Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small cell lung cancer: a 7-year assessment of a randomized controlled trial. *Lung Cancer* 1999;47:7-14.
- Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. *Lung Cancer* 1998;21:1-6.
- Rusch VW, Giroux DJ, Kraut MJ, et al. et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup trial 0160). *J Thorac Cardiovasc Surg* 2001; 121:472-483.

6. Behandeling gevorderde stadia Niet Kleincellig Longcarcinoma (NKCLC)

7. Behandeling "Limited Disease" Kleincellig Longcarcinoma (KCLC)

- Aupérin A, Arriagada R, Pignon J-P, et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. *N Engl J Med* 1999; 341: 476-484.
- Choi NC, Carey R. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small cell lung carcinoma: an update. *Int J Radiat Oncol Biol Phys* 1989; 17:307-310.
- Coolen L, Vanden Eeckhout A, Deneffe G, Demedts M, Vansteenkiste J. Surgical treatment of small cell lung cancer. *Eur J Cardiothorac Surg* 1995; 9:59-64.
- Chrystal K, Cheong K, Harper P. Chemotherapy of small cell lung cancer: state of the art. *Curr Opin Oncol* 2004; 16:136-140.
- De Ruyscher D, Vansteenkiste J. Chest radiotherapy in limited stage small cell lung cancer: Facts, questions, prospects. *Radiother Oncol* 2000; 55:1-9.

- Gregor A, Drings P, Burghouts J, et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. *J Clin Oncol* 1997; 15:2840-2849.
- Inoue M, Miyoshi S, Yasumitsu T, et al. Surgical results for SCLC based on the new TNM staging system. *Ann Thorac Surg* 2000; 70: 1615-1619.
- Komaki R, Meyers CA, Shin DM, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. *Int J Radiat Oncol Biol Phys* 1995; 33:179-182.
- Laurie SA, Logan D, Markman BR, Mackay JA, Evans WK. Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small cell lung cancer. *Lung Cancer* 2004; 43:223-240.
- Murray N, Coy, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer. *J Clin Oncol*. 1993; 11: 336-44.
- Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. *N Eng J Med*. 1992; 327: 1618-1624
- Stahel RA, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus. *Lung Cancer* 1989; 5:119-126.
- Szczesny TJ, Szczesna A, Shepherd FA, Ginsberg RJ. Surgical treatment of small cell lung cancer. *Semin Oncol* 2003; 30:47-56.
- Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. *J Clin Oncol* 2002; 20: 3054-3060.
- Turrisi AT, Kim K, Blum R, et al. Twice daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Eng J Med* 1999;340: 265-271.
- Van Oosterhout AG, Van de Pol M, Ten Velde GP, Twijnstra A. Neurologic disorders in 203 consecutive patients with small cell lung cancer. Results of a longitudinal study. *Cancer* 1996; 77:1434-1441.

8. Behandeling “Extensive Disease” Kleincellig Longcarcinoma (KCLC)

- Chua YJ, Steer C, Yip D. et al. Recent advances in management of small cell lung cancer. *Cancer Treat Rev* 2004; 30: 521-543.
- Girling DJ. Comparison of oral etoposide and standard intravenous multi-drug chemotherapy for small-cell lung cancer: a stopped multi-centre randomised trial. Medical Research Council Lung Cancer Working Party. *Lancet* 1996; 348:563-566.
- Huisman C, Postmus PE, Giaccone G, et al. Second-line chemotherapy and its evaluation in small cell lung cancer. *Cancer Treat Rev* 1999; 25:199-206.
- Johnson BE, Fischer T, Fischer B, et al. Phase II study of Imatinib in patients with small cell lung cancer. *Clin Cancer Res* 2003; 9:5880-5887.

- Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. *N Engl J Med* 2002; 346:85-91.
- Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. *Br J Cancer* 2000; 83:8-15.
- Sculier JP, Berghmans T, Castaigne C, et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. *Lung Cancer* 1998; 19:141-151.
- Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small cell lung cancer. *J Clin Oncol* 2002; 20:4434-4439.
- Tebbutt NC, Snyder RD, Burns WI. An analysis of the outcomes of treatment of small cell lung cancer in the elderly. *Aust NZ J Med* 1997; 27: 160-164.
- Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small cell lung cancer. *J Clin Oncol* 1999; 17:658-667.
- Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. *Lung Cancer* 2000; 28: 173-185.